Abliva AB (publ) announced that the Wave 1 cohort has completed 24 weeks of dosing in the ongoing Phase 2 FALCON trial of KL1333 for the treatment of primary mitochondrial disease. These data will be reviewed by the Independent Data Monitoring Committee (DMC), with results from the interim analysis expected in early Third Quarter 2024. In addition to evaluating the interim safety data, the DMC will make a recommendation as to whether to continue the study and advise on the final study size.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.136 SEK | -2.30% |
|
-9.33% | -44.60% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.60% | 17.86M | |
+16.45% | 122B | |
+21.96% | 116B | |
+24.43% | 27.03B | |
-20.05% | 20.36B | |
-16.61% | 16.43B | |
-16.28% | 15.91B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- ABLI Stock
- News Abliva AB
- Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease